Trial · NCT01439308
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Assessment of total symptom score (TSS) after unilateral, incremental dose, intranasal challenge with capsaicin | 0-4hours following dosing | |
| Primary | Assessment of total Ipsilateral secretion's weight after unilateral, incremental dose, intranasal challenge with capsaicin | 0-4hours following dosing | |
| Secondary | Change from baseline in peak nasal inspiratory flow (PNIF) after unilateral, incremental dose, intranasal challenge with capsaicin | 0-4hours following dosing | |
| Secondary | Assessment of Total Contralateral secretion's weight after unilateral, incremental dose, intranasal challenge with capsaicin | 0-4hours following dosing | |
| Secondary | Number of participants with Individual Symptoms as assessed by TSS components after unilateral, incremental dose, intranasal challenge with capsaicin | 0-4hours | |
| Secondary | Soluble biochemical mediators, including but not limited to neuropeptides, in nasal secretions induced after unilateral, incremental dose, intranasal challenge with capsaicin | 0-4hours following dosing | |
| Secondary | Intranasal, single dose SB-705498 plasma PK parameters-Cmax | 0-4hours | |
| Secondary | Intranasal, single dose SB-705498 plasma PK parameters- Tmax | 0-4hours post dosing | |
| Secondary | Intranasal, single dose SB-705498 plasma PK parameters- AUC(0-t) | 0-4hours post dosing | |
| Secondary | Number of participants with adverse events | Day 1 | |
| Secondary | Number of participants with vital signs data outside range of potential clinical importance- Systolic blood pressure (SBP) and diastolic blood pressure (DBP) | Day 1 | |
| Secondary | Heart rate | Day 1 | |
| Secondary | Number of participants with nasal examination data | Day 1 | |
| Secondary | Number of participants with abnormal ECG findings | Day 1 | |
| Secondary | Body temperature | Day 1 | |
| Secondary | Number of participants with abnormal hematology values | Day 1 | |
| Secondary | Number of participants with abnormal clinical chemistry values- Carbon dioxide content/Bicarbonate, Cholesterol, Potassium, Triglycerides | Day 1 | |
| Secondary | Number of participants with abnormal clinical chemistry values- Creatinine | Day 1 | |
| Secondary | Number of participants with abnormal clinical chemistry values- Gamma Glutamyl Transferase, Lactate Dehydrogenase | Day 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01439308/registered